Stocks Health care BMRN
NASDAQ · Health careBiomarin Pharmaceutical Inc (BMRN)
Biomarin Pharmaceutical Inc brought in $3.7B of revenue over the twelve months to September 30, 2026, up 18.1% from a year earlier. It posted a net loss of $19.1M. Operating cash flow minus capital spending left $725M of free cash flow in fiscal 2025. At September 30, 2026 it held $736M in cash against $4.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 3, 2026.
Key facts about Biomarin Pharmaceutical Inc
- Net worth
- Biomarin Pharmaceutical Inc has a market value (market cap) of $11.1B at the latest share price, and shareholders' equity of $6.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2025 revenue was $3.2B (+12.9% year on year), with net income of $348.9M. Over the 12 months to September 30, 2026: revenue $3.7B, net loss $19.1M.
- Cash flow
- In fiscal 2025 operations brought in $828M of cash; after $103M of capital spending, free cash flow was $725M.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 3, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Biomarin Pharmaceutical Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Biomarin Pharmaceutical Inc does
Biomarin Pharmaceutical Inc is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker BMRN.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $3.2B | $348.9M | $1.80 | $725M |
| 2024 | $2.9B | $426.9M | $2.21 | $487.4M |
| 2023 | $2.4B | $167.6M | $0.87 | $62.6M |
| 2022 | $2.1B | $141.6M | $0.75 | $54.9M |
| 2021 | $1.8B | -$64.1M | -$0.35 | $209M |
| 2020 | $1.9B | $854M | $4.50 | -$28.9M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Where BMRN ranks in Health care
Latest SEC filings
What Biomarin Pharmaceutical Inc has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 3, 2026Quarterly report 10-Q · period to September 30, 2026Revenue rose 32% to $1B versus the same quarter last year; diluted EPS -$0.63 versus -$0.16.
- November 2, 2026
- October 6, 2026Quarterly results8-KBioMarin expects third-quarter and full-year 2026 earnings to be reduced by charges related to its acquisition of Alesta Therapeutics.
- September 30, 2026Material agreement8-KBioMarin entered into a settlement and license agreement with Ascendis Pharma to resolve patent litigation and receive product royalties.
- September 15, 2026Other event 8-K
- September 14, 2026Executive or director change8-KBioMarin Pharmaceutical appointed Dr. Robert Plenge to its Board of Directors and expanded the board to eleven members.
- September 1, 2026Other event 8-K
- August 31, 2026
- August 18, 2026
- August 6, 2026
What is BMRN worth? A DCF from its reported cash flow
Insider trades
What the people running Biomarin Pharmaceutical Inc did with its shares, from the Form 4 filings they must send the SEC within two business days.
Insiders sold $1.2M worth of shares in the last 90 days and bought none on the open market.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 30, 2026 | Friberg Gregory REVP, Chief R&D Officer | Shares withheld for tax | 4,086 | $245.2K |
| September 10, 2026 | Plenge Robert MDirector | Received as pay | 6,140 | - |
| September 2, 2026 | Davis George EricEVP, Chief Legal Officer | Sold | 17,557 | $1.2M |
| June 2, 2026 | Anderson Elizabeth MDirector | Received as pay | 7,490 | - |
| June 2, 2026 | Bodem Barbara W.Director | Received as pay | 7,490 | - |
| June 2, 2026 | Clark Ian TDirector | Received as pay | 7,490 | - |
| June 2, 2026 | Dere Willard HDirector | Received as pay | 7,490 | - |
| June 2, 2026 | Enyedy Mark JDirector | Received as pay | 7,490 | - |
Who owns BMRN
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Primecap Management Co13G, passive | 8.24% | August 14, 2025 |
| Vanguard Capital Management13G, passive | 5.25% | April 29, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 564 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| BlackRock, Inc. | 20,445,212 | +626,911 |
| Dodge & Cox | 14,844,930 | +283,171 |
| Primecap Management Co | 14,190,183 | -3,822 |
| Vanguard Capital Management LLC | 8,743,633 | +100,469 |
| Vanguard Portfolio Management LLC | 8,648,678 | +350,203 |
| Norges Bank | 8,207,954 | new |
| State Street Corp | 7,800,959 | +505,880 |
| Viking Global Investors LP | 7,616,563 | +554,486 |
| Vestal Point Capital, LP | 6,025,000 | +2,450,000 |
| Aqr Capital Management LLC | 5,699,541 | -1,977,000 |
| Fmr LLC | 4,822,893 | +1,255,862 |
| Dimensional Fund Advisors LP | 4,075,714 | +272,784 |
| Geode Capital Management, LLC | 3,911,794 | +92,353 |
| Assenagon Asset Management S.A. | 3,524,172 | +1,603,514 |
| Capital Research Global Investors | 3,504,387 | +13,001 |
| Deep Track Capital, LP | 3,307,481 | +2,157,481 |
| Millennium Management LLC | 2,071,816 | -938,492 |
| Charles Schwab Investment Management Inc | 1,616,020 | +28,337 |
| First Trust Advisors LP | 1,606,273 | -66,218 |
| Northern Trust Corp | 1,558,104 | -28,280 |
Insiders
17 insiders reported holding 873,171 shares in total, about $49.9M at the last price.
| Holder | Shares |
|---|---|
| Hardy AlexanderChief Executive Officer, Director | 214,635 |
| Mueller BrianEVP, Chief Financial Officer | 123,314 |
| Guyer Charles GregEVP, Chief Technical Officer | 84,140 |
| Davis George EricEVP, Chief Legal Officer | 61,003 |
| Hombach Robert J.Director | 49,360 |
| Friberg Gregory REVP, Chief R&D Officer | 47,732 |
| Dere Willard HDirector | 46,440 |
| Hubbard CristinEVP, Chief Commercial Officer | 42,472 |
| Anderson Elizabeth MDirector | 41,940 |
| Ho MaykinDirector | 35,500 |
Questions about BMRN
What does Biomarin Pharmaceutical Inc do?
Biomarin Pharmaceutical Inc is a company in the Health care sector, listed on NASDAQ as BMRN. Its shares trade on NASDAQ under the ticker BMRN.
What is Biomarin Pharmaceutical Inc's net worth?
Biomarin Pharmaceutical Inc has a market value (market cap) of $11.1B at the latest share price, and shareholders' equity of $6.3B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Biomarin Pharmaceutical Inc profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $19.1M on revenue of $3.7B.
How much revenue does Biomarin Pharmaceutical Inc make?
Over the twelve months to September 30, 2026 Biomarin Pharmaceutical Inc reported revenue of $3.7B. That is 18.1% more than a year earlier.
When did Biomarin Pharmaceutical Inc last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 3, 2026. It covers the period to September 30, 2026.
When is Biomarin Pharmaceutical Inc's next earnings report?
Biomarin Pharmaceutical Inc's next report is expected around January 11, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare BMRN with
Follow BMRN
Get an email when Biomarin Pharmaceutical Inc files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Biomarin Pharmaceutical Inc tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.